NEW YORK (GenomeWeb News) – German molecular diagnostics firm SIRS-Lab said today that it will use a PCR technology platform from DxS in a sepsis pathogen-detection test in the European Union under a new licensing agreement.
SIRS-Lab will use the DxS Scorpions Technology with its Signature sepsis prediction and monitoring test, which it plans to make widely available in the EU in 2009. The companies also have agreed to include an option in the license that would allow SIRS-Lab to use the DxS PCR technology worldwide.
SIRS-Lab plans to start using the test in multi-center clinical trials, company CEO Stefan Russwurm said in a statement, and then the firm expects to make it available as an integrated test that will include pathogen detection and monitoring of host response.
SIRS-Lab will use transcriptomics biomarkers it has identified that it said indicate sepsis more reliably than other current measures.
DxS CEO Stephen Little said that the Scorpions technology's “high sensitivity, speed and specificity” make it ideal for use in infectious disease applications.
Financial terms of the agreement were not released.